Supernus Pharmaceuticals
SUPN
28.61
+0.26
+0.92%
Supernus Pharmaceuticals
US · SUPN
#2636 by market cap
Listed 1970
28.61
+0.26
+0.92%
Periodic snapshot; not a real-time feed.
· 2026-11-20 16:48
Recent news
-
Rating change
Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $67Market Newswire · 2026/7/9
-
Rating change
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $66Market Newswire · 2026/4/13
-
Rating change
Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $63Market Newswire · 2026/1/9
-
Piper Sandler Maintains Supernus(SUPN.US) With Buy Rating, Cuts Target Price to $47Market Newswire · 2026/11/5
-
Rating change
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $66Market Newswire · 2026/7/27
-
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $55Market Newswire · 2026/10/31
-
Company notice
Supernus Pharmaceuticals: Supernus Pharmaceuticals, Inc. - Anticipated Adjustment Option Symbol: SUPN New Symbol: SUPN1OCC · 2026/9/17
-
Stifel Maintains Supernus(SUPN.US) With Hold Rating, Cuts Target Price to $37Market Newswire · 2026/11/5
-
Rating change
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $65Market Newswire · 2026/2/25
-
Company notice
Supernus: Supernus Pharmaceuticals, Inc. - Contract Adjustment Option Symbol: 11/02/2026 - SUPN Remains SUPN 11/03/2026 - SUPN Becomes SUPN1OCC · 2026/11/2
-
Rating change
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2025/11/5
-
Company notice
Supernus: Supernus Pharmaceuticals, Inc. - Contract Adjustment Option Symbol: 11/02/2026 - SUPN Remains SUPN 11/03/2026 - SUPN Becomes SUPN1 * * * Update * * *OCC · 2026/11/3
-
Rating change
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/1/28
-
Company notice
Indivior: Indivior Pharmaceuticals, Inc. - Cash Distribution and Name/Symbol Change Option Symbol: INDV New Symbol: SUPNOCC · 2026/11/3
-
Rating change
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/10/21
-
Rating change
BofA Securities Initiates Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Announces Target Price $63Market Newswire · 2026/7/13
-
News On Indivior Pharmaceuticals Inc. (INDV) Now Under SUPNDow Jones · 2026/11/4
-
Rating change
BofA Securities Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/2/25
-
Cantor Fitzgerald Maintains Supernus(SUPN.US) With Buy Rating, Raises Target Price to $87Market Newswire · 2026/11/5
-
Rating change
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Raises Target Price to $55Market Newswire · 2025/12/19
-
Rating change
Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $63Market Newswire · 2025/9/30
-
Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q2 Net Loss $1.01 a Share, Vs. FactSet Est of $0.04 EPSMT Newswires · 2026/8/3
-
Rating change
Piper Sandler Upgrades Supernus Pharmaceuticals(SUPN.US) to Buy Rating, Raises Target Price to $65Market Newswire · 2025/10/9
-
Rating change
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Raises Target Price to $43Market Newswire · 2025/8/7
-
Rating change
Cantor Fitzgerald Upgrades Supernus Pharmaceuticals(SUPN.US) to Buy Rating, Raises Target Price to $42Market Newswire · 2025/7/30
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 16:48:01 · For reference only, not investment advice and not tailored to your situation.
Supernus Pharmaceuticals discussion 0 comments